Inventage Lab is seeking to launch an Australian Phase 1 clinical trial of a long-acting obesity treatment designed to be administered once a month. The company plans to gather human pharmacokinetic and safety data to pursue partnerships and licensing agreements with global pharmaceutical companies.
The drug delivery platform company announced on the 28th that it had submitted an investigational new drug (IND) application in Australia for IVL3021, a long-acting injectable formulation based on semaglutide.
IVL3021 is an investigational drug being developed to replace existing once-weekly semaglutide treatments with a once-monthly injection. The company said preclinical animal studies demonstrated weight-loss effects comparable to those observed in animals repeatedly treated with Wegovy. It also reported that animals switched to IVL3021 after receiving Wegovy maintained their weight.
The drug candidate incorporates Inventage Lab’s long-acting drug delivery platform, IVL-DrugFluidic. The company aims to reduce the initial burst release of the drug immediately after administration and maintain its therapeutic effects over an extended period. The planned clinical trial will evaluate pharmacokinetics, tolerability and other parameters in humans.
Inventage Lab plans to explore partnerships with global pharmaceutical companies based on data generated in the clinical trial. It also intends to apply the experience gained from this study to the development of IVL3024, a follow-on candidate based on tirzepatide.
The company is also developing long-acting injectable treatments for other conditions, including hair loss, dementia and drug addiction.
Founded in 2015, Inventage Lab is a drug delivery platform company developing medicines designed to extend dosing intervals and maintain consistent therapeutic effects using IVL-DrugFluidic, its long-acting injectable manufacturing technology.
The company has used its proprietary platform to develop long-acting injectable treatments across several therapeutic areas, including dementia, drug addiction and obesity, while pursuing joint development projects and licensing agreements with pharmaceutical and biotechnology companies in South Korea and abroad. Recently, it has focused on global clinical development and commercialization of long-acting injectables, including IVL3004, a candidate for treating drug addiction.
